Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.

Brokerage firm Jefferies is positive on the shares of Biocon Limited. The broking has upgraded the ratings of the pharma ...

Zomato slips on Jefferies' downgrade, Biocon rallies on USFDA approval and Jefferies upgrade, ONGC gains as CLSA names it a ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

International brokerage Jefferies has upgraded its rating on drugmaker Biocon to 'hold' citing positive newsflow around the regulatory approval of its Bengaluru manufacturing unit. Building on the ...

Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.) ...

Save your favourite. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement.

Biocon stock price today: Shares of Kiran Mazumdar Shaw-led Biocon extended gains to settle five per cent higher on Tuesday, December 24, after the United States Food and Drug Administration ...